COVID-19 and Cancer Consortium Wins the NIH/FASEB DataWorks! Prize Challenge
If you are interested in the impacts of COVID-19 on those who treat and are affected by cancer, you may want to check out the winners of the 2023 DataWorks! Grand Prize. The COVID-19 & Cancer Consortium (CCC19) studies the uncertain impact of the COVID-19 pandemic on those affected by cancer. The annual award, a partnership between NIH and the Federation of American Societies for Experimental Biology (FASEB), recognizes exceptional data practices in biological and biomedical research.
CCC19 develops a robust and agile strategy to collect and disseminate vital patient information. Its approach includes three significant components:
- agile data sourcing and acquisition,
- robust data and quality management, and
- public sharing of a rapidly evolving data model.
To catalyze clinical research, CCC19 established a data sharing platform that spanned 126 cancer institutions across North America, resulting in the largest registry of its kind, with over 19,000 cases that are available for you to view.
[callout] View the aggregate data by visiting the CCC19 registry. [/callout]
CBIIT’s Dr. Jill Barnholtz-Sloan, a member of CCC19’s scientific executive committee, says, “I congratulate CCC19 on their remarkable achievement in winning the NIH/FASEB’s DataWorks! Prize. Since its start in 2020, CCC19 has made significant progress in our understanding of how COVID-19 impacts individuals with cancer. This important collaboration brings together more than 120 cancer centers to facilitate
CCC19’s transparent and streamlined approach to data management highlights the significance of